Log In
Print this Print this

resiquimod 0.06% gel

  Manage Alerts
Collapse Summary General Information
Company Galderma S.A.
DescriptionTopical resiquimod gel
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationBasal cell carcinoma (BCC)
Indication DetailsTreat nodular basal cell carcinoma (BCC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today